Resultados de la búsqueda 771-780 of 4764 for Lupus

  1. Oncología (médica) - Ensayos clínicos

    Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...

  2. Hematología - Ensayos clínicos

    This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the ...

  3. Oncología (médica) - Ensayos clínicos

    This protocol allows multiple treatments with TheraSphere® that may be delivered on an outpatient basis. Patients may receive a single dose to a liver lobe ...

  4. Oncología (médica) - Ensayos clínicos

    This study aims to identify candidate High Grade Serous Cancer (HGSC) early detection and chemotherapy treatment response biomarkers. For the purpose of this ...

  5. Cirugía - Ensayos clínicos

    Levels of bladder cancer-derived extracellular vesicles become undetectable after radical cystectomy in patients with localized bladder cancer. This study hopes ...

  6. Ensayos clínicos - Neurología

    This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to ...

  7. Ensayos clínicos - Neurología

    This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to ...

  8. Oncología (médica) - Ensayos clínicos

    A Study Of The Drugs Selumetinib Vs. Carboplatin And Vincristine In Patients With Low-Grade Glioma. Rochester, Minn. This study aims to demonstrate that the ...

  9. Oncología (médica) - Ensayos clínicos

    Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...

  10. Oncología (médica) - Ensayos clínicos

    The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status. The percentage ...